Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 2-Apr 4:05 PM ET)
Market Chameleon (Tue, 17-Mar 4:43 AM ET)
Globe Newswire (Tue, 17-Mar 8:05 AM ET)
Globe Newswire (Thu, 12-Mar 8:05 AM ET)
Globe Newswire (Mon, 9-Mar 8:05 AM ET)
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
Globe Newswire (Tue, 24-Feb 8:05 AM ET)
Candel Therapeutics Targets $100 Million Public Offering to Accelerate Cancer Therapy Development
Market Chameleon (Fri, 20-Feb 2:31 AM ET)
Candel Therapeutics Announces Pricing of Public Offering
Globe Newswire (Thu, 19-Feb 9:40 PM ET)
Candel Therapeutics Announces Proposed $100 Million Public Offering
Globe Newswire (Thu, 19-Feb 4:05 PM ET)
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Candel Therapeutics trades on the NASDAQ stock market under the symbol CADL.
As of April 27, 2026, CADL stock price declined to $6.47 with 464,282 million shares trading.
CADL has a beta of 1.48, meaning it tends to be more sensitive to market movements. CADL has a correlation of 0.10 to the broad based SPY ETF.
CADL has a market cap of $473.91 million. This is considered a Small Cap stock.
In the last 3 years, CADL traded as high as $14.60 and as low as $.66.
The top ETF exchange traded funds that CADL belongs to (by Net Assets): VTI, IWM, IBB, VXF, IWO.
CADL has underperformed the market in the last year with a return of +29.4%, while SPY returned +31.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CADL shares. However, CADL has outperformed the market in the last 3 month and 2 week periods, returning +4.4% and +34.0%, while SPY returned +3.7% and +4.9%, respectively. This indicates CADL has been having a stronger performance recently.
CADL support price is $6.19 and resistance is $6.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CADL shares will trade within this expected range on the day.
